We are live on ! Find out more
JSPR icon

Jasper Therapeutics

23 hedge funds and large institutions have $161M invested in Jasper Therapeutics in 2021 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,408% more capital inflows, than outflows

Capital inflows: $103M | Capital outflows: $4.09M

639% more call options, than puts

Call options by funds: $2.02M | Put options by funds: $274K

325% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 4

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

130% more funds holding

Funds holding: 10 → 23 (+13)

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

29.96% more ownership

Funds ownership: 27.25% → 57.21% (+30%)

Holders
23
Holders Change
+13
Holders Change %
+130%
% of All Funds
0.35%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
17
Increased
3
Reduced
2
Closed
4
Calls
$2.02​M
Puts
$274​K
Net Calls
+$1.75​M
Net Calls Change
+$1.75​M

JSPR Hedge Fund Activity: Q4 2021 in Review

23 of the 6,524 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q4 2021, worth a combined $161M — up 57% from $102M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new JSPR positions and 4 closed out — a net gain of 13 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Kingdon Capital Management, opening a new position worth an estimated $5.05M. The largest seller was Federated Hermes, cutting an estimated $2.75M.

  • 23 institutional investors held Jasper Therapeutics (JSPR) as of Q4 2021, up from 10 in Q3 2021.
  • Funds reported $161M of Jasper Therapeutics stock for Q4 2021, up 57% quarter-over-quarter.
  • 17 funds opened new Jasper Therapeutics positions in Q4 2021 and 4 closed out, a net change of +13 holders.
  • The largest Jasper Therapeutics buyer in Q4 2021 was Kingdon Capital Management, an estimated $5.05M added.
  • The largest Jasper Therapeutics seller in Q4 2021 was Federated Hermes, an estimated $2.75M sold.

Based on aggregated 13F filings for Q4 2021.